The U.S. Food and Drug Administration’s approvals of Enhertu for various metastatic breast cancers last year sparked renewed interest in antibody-drug conjugates (ADCs). These recent approvals demonstrate how precisely engineering ADC components can help overcome the therapeutics inherent shortcomings. Building on this momentum, the industry is addressing acquired resistance, tumor heterogeneity, and off-target toxicity by going beyond conventional formats.
In this GEN webinar, experts from ChemPartner, Philip Clarke, PhD, Hu Liu, PhD, and Greg Liang, MD, will provide an overview of some of the innovative platforms that are shaping the next-generation of antibody-drug conjugates. During the webinar, they will use several case studies to demonstrate how novel antibody formats and linker chemistries expand the therapeutic window. Key takeaways include:
- Multi-targeting precision: Learn how trispecific, bispecific, and biparatopic antibodies can improve internalization and binding avidity.
- New linker technology: An overview of the exclusive C2.LP double-cleavage linker system and how this technology greatly reduces off-target cytotoxicity by enhancing stability in vivo.
- Overcoming resistance with dual-payloads: Using dual-payload ADCs to target several cellular pathways at once, avoiding resistance mechanisms.
A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.
Produced with support from:
